中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

37 records (took 0.019 seconds)

    Activity mode for artificial pancreas system
    21.
    发明授权
    Activity mode for artificial pancreas system 有权

    公开(公告)号：US11628251B2

    公开(公告)日：2023-04-18

    申请号：US16586440

    申请日：2019-09-27

    Applicant: INSULET CORPORATION

    Inventor： Jason O'Connor ,  Joon Bok Lee ,  Trang Ly ,  Todd Vienneau ,  Yibin Zheng ,  Ashutosh Zade

    IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

    Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.

    User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
    23.
    发明授权
    User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system 有权

    公开(公告)号：US11547800B2

    公开(公告)日：2023-01-10

    申请号：US16789051

    申请日：2020-02-12

    Applicant: Insulet Corporation

    Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor

    IPC: A61M5/172 ,  A61K38/28 ,  A61M31/00 ,  G16H40/63 ,  A61M5/142

    Abstract: Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

    COMPENSATION FOR MISSING READINGS FROM A GLUCOSE MONITOR IN AN AUTOMATED INSULIN DELIVERY SYSTEM
    24.
    发明申请
    COMPENSATION FOR MISSING READINGS FROM A GLUCOSE MONITOR IN AN AUTOMATED INSULIN DELIVERY SYSTEM 有权

    公开(公告)号：US20210252219A1

    公开(公告)日：2021-08-19

    申请号：US16791648

    申请日：2020-02-14

    Applicant: Insulet Corporation

    Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'Connor

    IPC: A61M5/172 ,  G06F17/17

    Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

    Initial total daily insulin setting for user onboarding
    25.
    发明授权
    Initial total daily insulin setting for user onboarding 有权

    公开(公告)号：US12257420B2

    公开(公告)日：2025-03-25

    申请号：US18436410

    申请日：2024-02-08

    Applicant: INSULET CORPORATION

    Inventor： Joon Bok Lee ,  Mengdi Li ,  Jason O'Connor ,  Yibin Zheng

    IPC: G08B1/08 ,  A61M5/172 ,  G16H10/40 ,  G16H10/60 ,  G16H20/17 ,  G16H40/60 ,  G16H40/67 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  H04L67/141

    Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

Patent Agency Ranking